Impact of weight status on risk of venous thromboembolism associated with GLP-1 receptor agonists
Authors:
- 17 September 2025
- journal article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 18 (12) , 1023-1026
Abstract
No abstract availableKeywords
Funding Information
- Conquer Cancer Foundation
- National Blood Clot Alliance
This publication has 13 references indexed in Scilit:
- Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trialsJournal of Thrombosis and Haemostasis, 2025
- 0781 Impact of Glucagon-Like Peptide-1 Analogs on Thromboembolic Outcomes in Obstructive Sleep Apnea PatientsSLEEP, 2025
- The Impact of GLP-1 Analogs on Thromboembolic Outcomes in Patients With SarcoidosisAmerican Journal of Respiratory and Critical Care Medicine, 2025
- GLP-1-based therapies for diabetes, obesity and beyondNature Reviews Drug Discovery, 2025
- Bariatric Surgery and the Long-Term Risk of Venous Thromboembolism: A Population-Based Cohort StudyObesity Surgery, 2024
- Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetesRedox Biology, 2023
- Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trialDiabetes, Obesity and Metabolism, 2022
- Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet ActivationJACC: Basic To Translational Science, 2022
- Long-term Impact of Bariatric Surgery on Venous Thromboembolic RiskAnnals of Surgery, 2019
- Diabetes mellitus as a prothrombotic conditionJournal of Internal Medicine, 2007